Tra-Mi Phan, MD MSc MBA

- ad interim Global Head of Medical Affairs since Feb 2025 - Responsible for elevating nutrition in the management of diabetes and obesity through scientific dialogue, HCP and patient education, omnichannel engagement, evidence generation - Close collaboration with R&D and Commercial on product development and platform strategy

- Drive strategic plans and projects that impact the long term Biosimilars business - Foster end-to-end thinking and collaboration across the value chain

- Responsible for the Neuroscience Business Franchise growth and portfolio lifecycle management (migraine, multiple sclerosis). Successful launches of 2 products in highly competitive markets - Lead the Marketing & Sales teams, oversee execution of pre-launch and launch plans across all line functions (Commercial, Medical, Access). Enhance new customer engagement models (e.g. cross-functional omnichannel touchpoints, beyond-the-molecule disease management) - Member of the Pharma Executive Committee

- Responsible for driving Novartis Pharma Schweiz (NPS) Medical Affairs strategy planning and successful execution, talent management and oversight of Clinical Operations in Switzerland. Represent NPS at key external scientific, clinical, medical and regulatory events. Provide input to Western Europe Cluster and Region Europe Medical and Clinical strategies and tactics. - Member of the Pharma Executive Committee. - Member of the Western Europe Cluster CSOs, Global Drug Development Cluster network. Therapeutic areas: Cardio-Renal & Metabolic, Respiratory, Immunology/Hepatology, Dermatology, Rheumatology, Neurology and Ophthalmology

- Diabetes and Obesity portfolio - Led the Regional Medical Affairs and Medical & Science team to drive successful planning and execution of Medical Affairs activities for the product portfolio across Europe, and to ensure that Global Product Development Plans address Region Europe business needs - Provided Medical input to cross-functional teams and Affiliates in lifecycle management, strategy development and implementation - Ensured strong medical dialogue with healthcare professionals and key decision-makers in the Region - Built and drove 2 large European real world studies that led to optimal product reimbursement

- Diabetes and Obesity portfolio - Drove Medical Affairs strategy planning and execution across the Region for solid launch preparedness in Affiliates. Provided regional guidance and training on the Medical Excellence framework leading to increased operational effectiveness. Ensured close alignment between Global, Regional and Local strategies - Provided Medical input to Marketing and Market Access/HEOR on product lifecycle management and real world data generation - Built solid relationships with European key opinion leaders (KOLs)

- Hospital care: pain management, critical care, infusion system and IV solutions, oncology - Provided Medical advisory to Marketing plans and tactics, to Regulatory Affairs & Market Access for registration and value dossiers - Performed health hazard analysis and implemented measures to secure patient safety - Evaluated in-licensing and acquisition opportunities with Business Development

- Activa® therapy - deep brain stimulation (DBS) - for Parkinson’s disease and neuro-psychiatric disorders - Established innovative market development solutions to increase adoption of a surgical therapy by the medical community and patients - Developed annual Regional Marketing strategic plan, tactics and core promotional material - Secured support of patient advocacy groups and developed their competencies, to broaden patient access to DBS therapy - Built and expanded network of European opinion leaders in Neurology and Neurosurgery

- Cardiovascular blockbuster co-promoted with Bristol-Myers Squibb. Launch of a new indication - Provided medical input to Affiliate plans and tactics. Managed clinical and real world evidence studies - Contributed to the successful launch of a new indication in the prevention of diabetic kidney disease - Built a multi-disciplinary education program with KOLs in cardiology, nephrology and diabetes

- Cardiovascular blockbusters - Contributed to Medical and Marketing strategy and tactics, developed internal and external education programs - Managed Phase 3b/4 clinical studies

Oncology